临床误诊误治2024，Vol.37Issue(3) ：114-118.DOI:10.3969/j.issn.1002-3429.2024.03.023

胸腺法新对紫杉醇、顺铂联合方案治疗中晚期食管癌增效减毒作用研究

Study on the Synergistic and Attenuating Effects of Thymalfasin on Paclita-xel Combined with Cisplatin Regimen in the Treatment of Advanced Esophageal Cancer

徐长龙 王仟慧
临床误诊误治2024，Vol.37Issue(3) ：114-118.DOI:10.3969/j.issn.1002-3429.2024.03.023
✕
  • 维普
  • 万方数据

胸腺法新对紫杉醇、顺铂联合方案治疗中晚期食管癌增效减毒作用研究

Study on the Synergistic and Attenuating Effects of Thymalfasin on Paclita-xel Combined with Cisplatin Regimen in the Treatment of Advanced Esophageal Cancer

徐长龙 1王仟慧2
扫码查看

作者信息

  • 1. 239399 安徽 天长,天长市人民医院肿瘤科
  • 2. 239399 安徽 天长,天长市人民医院消化内科
  • 折叠

摘要

目的 探究胸腺法新对紫杉醇联合顺铂(TP)方案治疗中晚期食管癌的增效减毒作用.方法 选取2021 年6 月—2023 年6 月收治的中晚期食管癌120 例,随机分为观察组和对照组,各60 例.对照组行TP方案治疗,观察组行胸腺法新联合TP方案治疗.比较2 组疗效、生活质量改善率、毒副反应、1 年生存率及T淋巴细胞亚群、癌胚抗原(CEA)、鳞状细胞癌抗原(SCC-Ag)、糖类抗原 19-9(CA19-9)水平.结果 观察组客观缓解率、生活质量改善率及1 年生存率高于对照组,恶心呕吐、骨髓抑制发生率低于对照组(P<0.05);治疗 1、4 个疗程,观察组CD8 +、CD4 +、CD3 +、CD4 +/CD8 +较对照组改善幅度大(P<0.05);2 组治疗1、4 个疗程血清CEA、SCC-Ag及CA19-9 水平均较治疗前下降,且观察组较对照组低(P<0.05).结论 胸腺法新可通过增强机体免疫功能对TP方案治疗中晚期食管癌发挥增效减毒作用.

Abstract

Objective To explore the synergistic and attenuating effects of Thymalfasin on paclitaxel combined with cisplatin(TP)regimen in the treatment of advanced esophageal cancer.Methods A total of 120 patients with moderate and advanced esophageal cancer treated from June 2021 to June 2023 were randomly divided into observation group(n =60)and control group(n =60).The control group was treated with TP regimen,and the observation group was treated with Thymalfa-sin combined with TP regimen.The efficacy,improvement rate of quality of life,toxicity,1-year survival rate and the levels of T lymphocyte subsets,carcinoembryonic antigen(CEA),squamous cell carcinoma antigen(SCC-Ag)and carbohydrate anti-gen 19-9(CA19-9)before and after treatment were compared between the two groups.Results The objective remission rate,improvement rate of quality of life and 1-year survival rate in observation group were higher than those in control group,while the incidence of nausea,vomiting and myelosuppression was lower than that in control group(P<0.05).After 1 and 4 cour-ses of treatment,CD8 +,CD4 +,CD3 +,and CD4 +/CD8 + in the observation group had a higher improvement than that in the control group(P<0.05).Serum CEA,SCC-Ag and CA19-9 levels in the two groups after 1 and 4 courses of treatment were lower than those before treatment,and lower in the observation group than in the control group(P<0.05).Conclusion Thymalfasin can enhance the immune function of the body and play a synergistic and attenuating role in the treatment of ad-vanced esophageal cancer by TP regimen.

关键词

食管肿瘤/增效减毒/紫杉醇/胸腺法新/顺铂/T淋巴细胞/癌胚抗原/鳞状细胞癌抗原

Key words

Esophageal neoplasms/Synergistic and attenuating effect/Paclitaxel/Thymalfasin/Cisplatin/T-Lymphocytes/Carcinoembryonic antigen/Squamous cell carcinoma antigen

引用本文复制引用

基金项目

安徽省重点研发计划(2019)(201904407020060)

出版年

2024
临床误诊误治
解放军白求恩国际和平医院

临床误诊误治

CSTPCD
影响因子：0.914
ISSN：1002-3429
参考文献量25
段落导航相关论文